Afrine Nasal

symptomatic treatment of rhinitis (runny nose) of allergic and / or infectious-inflammatory etiology,

sinusitis,

evstahiit,

hay fever.

acute respiratory illness with symptoms of rhinitis,

acute allergic rhinitis,

exacerbation of vasomotor rhinitis,

to facilitate the outflow discharge from the sinuses in sinusitis, Eustachian, otitis media,

to eliminate edema before diagnostic manipulations in the nasal passages.

To facilitate nasal breathing when:

colds,

flu,

respiratory viral infections,

acute rhinitis,

sinusitis.

The intranasal route. Before each use, it is necessary to shake the spray bottle vigorously. Before the first application of the nasal spray, it is necessary to "calibrate" it by pressing the spray head several times.

Adults and children over 6 years of age — 2-3 injections in each nasal passage at intervals of 10-12 hours. The frequency of use can be increased up to 3 times a day in adults. It is not recommended to exceed the specified dose.

The intranasal route.

Nazivin^® Sensitive nasal drops 0.01% are intended for instillation in the nose of children under the age of one year. 1 drop of Nasivin^® Sensitive 0.01% contains 2.8 micrograms of oxymetazoline hydrochloride.

Children under the age of 4 weeks are prescribed 1 drop of Nasivin^® Sensitive in each nostril 2-3 times a day. From the 5th week of life to 1 year — 1-2 drops in each nostril 2-3 times a day.

Before use, the bottle should be turned over. The drug should be instilled with the child's head thrown back.

The effectiveness of the following procedure is also proven: depending on the age of 1-2 drops of Nasivin^® The sensitive is applied to cotton wool and rubbed over each nostril. At the recommended dose, do not use for more than 5-7 days without consulting a doctor. If symptoms worsen or do not improve within 3 days, you should consult your doctor.

Doses higher than recommended can only be used under the supervision of a doctor.

Insert the nozzle of the bottle into each nasal passage and press sharply once on the bottle. During the injection, the air is drawn in through the nose. When injecting Noxpray, do not throw your head back.

Adults and children over 12 years of age - 1-2 injections in each nasal passage. Repeat the injection no earlier than after 12 hours. Children from 6-12 years old (under adult supervision) - 1 injection every 12 hours.

The intranasal route.

Adults and children over 10 years of age — 1-2 injections in each nasal passage, maximum 2-3 times a day.

Children from 6 to 10 years — 1 injection in each nasal passage, maximum 2-3 times a day.

Duration of treatment: it is not recommended to use the drug for more than 7 days. With frequent or prolonged use of the drug, the feeling of difficulty in nasal breathing may reappear or worsen. If these symptoms occur, stop treatment and consult a doctor. When injecting, do not throw your head back and do not spray while lying down.

hypersensitivity to sympathomimetic agents, any component of the drug,

atrophic rhinitis,

concomitant use of MAO inhibitors (including a period of 14 days after their withdrawal),

children under 6 years of age.

With caution: coronary artery disease, arrhythmias, chronic heart failure, severe atherosclerosis, hypertension, hyperthyroidism, diabetes mellitus, chronic renal failure, angle-closure glaucoma,prostatic hyperplasia with clinical symptoms, pregnancy, lactation.

hypersensitivity to the components of the drug,

atrophic rhinitis,

angle-closure glaucoma.

With caution: severe diseases of the cardiovascular system, severe metabolic disorders.

hypersensitivity to the components of the drug,

atrophic rhinitis,

pregnancy, lactation,

children under 6 years of age.

With caution: CVD diseases (arterial hypertension, CHD, chronic heart failure, tachycardia, arrhythmias), angle-closure glaucoma, hyperthyroidism, diabetes mellitus, pheochromocytoma, chronic renal failure, simultaneous administration of MAO inhibitors, tricyclic antidepressants.

In general, the drug is well tolerated, and possible adverse events are usually mild and transient.

Transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing, increased blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disorders. With prolonged use — tachyphylaxis, reactive hyperemia and atrophy of the nasal mucosa. Benzalkonium chloride, which is part of the drug, can cause local skin reactions.

Dryness of the nasal mucosa, sneezing, severe nasal congestion (reactive hyperemia) - from ≥1 to <10%.

Increased blood pressure, tachycardia - from ≥0.1 to <1%.

Headache, insomnia - from ≥0.01 to <0.1%.

Side effects due to the systemic effect of the drug: dizziness, anxiety, irritability, sleep disorders (in children), exanthema, visual impairment (in contact with the eyes).

Prolonged or continuous use of vasoconstrictive drugs can lead to tachyphylaxis, atrophy of the nasal mucosa and recurrent edema of the nasal mucosa (drug-induced rhinitis).

Transient dryness and burning of the nasal mucosa, dry mouth and throat, sneezing, increased volume of secretions released from the nose. There may be an increase in blood pressure, increased anxiety, nausea, dizziness, headache, insomnia, palpitations, sleep disorders. With prolonged use — tachyphylaxis, reactive hyperemia of the mucous membrane (a feeling of nasal congestion) and atrophy of the nasal mucosa.

Symptoms: with a significant overdose or accidental ingestion, nausea, vomiting, cyanosis, fever, tachycardia, arrhythmia, increased blood pressure, shortness of breath, mental disorders, central nervous system depression (drowsiness, decreased body temperature, bradycardia, decreased blood pressure, respiratory arrest and coma) are possible.

Treatment: symptomatic. In case of accidental ingestion-gastric lavage, activated charcoal. Vasopressor medications are contraindicated.

Symptoms: nausea, increased blood pressure, tachycardia, central nervous system depression.

Treatment: symptomatic.

Overdose with local nasal use sometimes leads to such systemic effects as increased heart rate (tachycardia) and increased blood pressure. In rare cases-anxiety, insomnia, fatigue, headaches and nausea.

Treatment: symptomatic.

Alpha-given tool for local application. It has a vasoconstrictive effect. Oxymetazoline causes vasoconstriction of the mucous membranes of the nose, paranasal sinuses and Eustachian tube, which leads to a decrease in their edema and the release of nasal breathing in allergic and / or infectious-inflammatory rhinitis (runny nose).

Due to the presence of excipients in the composition of the drug (MCC, sodium carmellose and povidone K29–32) Afrin^® nasal moisturizing spray does not flow out of the nose and does not flow down the throat, because after being injected into the nasal passages, the spray becomes more viscous and is held on the nasal mucosa more effectively than a standard aqueous solution. This medicine contains moisturizing substances (glycerol and macrogol 1450) that help to retain moisture, which helps to provide hydration to dry or irritated nasal mucosa.

According to clinical studies, the drug begins to act within 1 min, and the action lasts up to 12 hours.

Nazivin^® Sensitive (oxymetazoline) has a vasoconstrictive effect. When applied topically to the inflamed nasal mucosa, it reduces its puffiness and nasal discharge. Restores nasal breathing. Elimination of edema of the nasal mucosa contributes to the restoration of aeration of the paranasal sinuses of the nasal cavity, the middle ear cavity, which reduces the likelihood of bacterial complications of respiratory diseases (sinusitis, sinusitis, otitis media). With local intranasal use in therapeutic concentrations, it does not irritate and does not cause hyperemia of the nasal mucosa. Oxymetazoline begins to act quickly, within 15 minutes. Duration of action of Nasivin^® Sensitive — up to 12 hours.

Oxymetazoline hydrochloride causes vasoconstriction of the nasal mucosa, paranasal sinuses, and Eustachian tube, which causes a mild and prolonged reduction in their edema and leads to easier nasal breathing. Relief of nasal breathing occurs 5-10 minutes after injection into the nasal cavity and lasts about 10-12 hours.

When used as a nasal spray, oxymetazoline is practically not detected in the blood plasma.

With local intranasal use, the drug does not have a systemic effect. T_1/2 oxymetazoline with its intranasal administration is 35 hours. 2.1% of oxymetazoline is excreted in the urine and about 1.1% - in the feces.

Slows the absorption of local anesthetic drugs, lengthens the time of their action.

Concomitant use with other vasoconstrictor drugs increases the risk of side effects.

With the simultaneous use of MAO inhibitors (including a period of 14 days after their withdrawal), maprotilin and tricyclic antidepressants-an increase in blood pressure.

Slows the absorption of local anesthetic drugs from the nasal cavity, lengthens their action.

Overdose or ingestion of oxymetazoline and the use of tricyclic antidepressants or MAO inhibitors simultaneously or immediately before the use of oxymetazoline can lead to an increase in blood pressure.

Slows the absorption of local anesthetic drugs, lengthens their action.

Co-administration of other vasoconstrictive drugs increases the risk of side effects.